Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Are You Looking for a High-Growth Dividend Stock?
04:45pm, Monday, 27'th Feb 2023 Zacks Investment Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Are You Looking for a High-Growth Dividend Stock?
12:48pm, Monday, 27'th Feb 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?
Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo
03:30pm, Friday, 24'th Feb 2023 Zacks Investment Research
FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.
The Zacks Analyst Blog Highlights ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard
08:58am, Friday, 24'th Feb 2023 Zacks Investment Research
ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard are included in this Analyst Blog.
Top Research Reports for Exxon Mobil, Coca-Cola & AstraZeneca
04:12pm, Thursday, 23'rd Feb 2023 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), The Coca-Cola Company (KO) and AstraZeneca PLC (AZN).
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
02:15pm, Thursday, 23'rd Feb 2023 Zacks Investment Research
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
AstraZeneca signs deal to produce new gastric cancer drug
06:29am, Thursday, 23'rd Feb 2023
AstraZeneca PLC (LSE:AZN), Britain's largest pharmaceutical company, has agreed a licensing deal with KYM Biosciences Inc for a potential drug treatment for gastric cancer. The deal will be split int
Apellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues
06:56pm, Wednesday, 22'nd Feb 2023 Zacks Investment Research
Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
11:20am, Tuesday, 21'st Feb 2023 Zacks Investment Research
Sector ETF report for PPH
Don't fall into the Intel dividend trap: These fund managers find the stocks with growing payouts
03:15pm, Saturday, 18'th Feb 2023 MarketWatch
A rising dividend strategy can help you grow your investment portfolio and eventually provide a stream of income when you need it.
9 February Inflation-Busting Ideal Dividend Dogs
07:15pm, Friday, 17'th Feb 2023
March-April, 2022, UBS, Kiplinger, and Barron's analysts and reporters combined to list five sets of stocks sorted as: “Inflation Busters.” Those five articles revealed 48 equities, with 43 paying
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases
04:11pm, Friday, 17'th Feb 2023 Zacks Investment Research
Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.
This chart offers one reason that European stocks may continue to outperform U.S. equities
12:38pm, Friday, 17'th Feb 2023 MarketWatch
One of the stories for markets this year has been the outperformance of European stocks to U.S. ones
FTSE 100 hits fresh record above 8,000 on weak pound and renewed demand for energy stocks
03:08pm, Thursday, 16'th Feb 2023 MarketWatch
The U.K.'s FTSE 100 hit 8,000 for the first time as investors warm to its mix of low-valued blue-chips, such as energy, mining and financials.
3 Stocks To Buy As U.S. Inflation Stays Sticky
08:00am, Thursday, 16'th Feb 2023
The latest inflation numbers from the US at 6.4% YoY show disinflation is ongoing but more Fed rate hikes are likely too, increasing the chances of a recession. The three stocks selected here face low
